If You Invested in Cue Biopharma Inc (CUE)

Cue Biopharma, Inc. (CUE) is a clinical-stage biopharmaceutical company focused on research and development in biotechnology. Traded on Nasdaq under the ticker CUE, the company is headquartered in Boston, Massachusetts and operates within the professional, scientific, and technical services sector. Cue Biopharma is developing a novel class of injectable biologic drug candidates designed to selectively engage and modulate disease-specific T cells directly within a patient’s body.

The company’s work centers on the human immune system, with programs in both autoimmune disease and cancer. Cue Biopharma describes its proprietary platform, Immuno-STAT® (Selective Targeting and Alteration of T cells), as a way to harness the curative potential of the body’s intrinsic immune system while aiming to avoid the adverse effects associated with broad systemic immune modulation. According to multiple company disclosures, its Immuno-STAT biologics are engineered to deliver highly targeted immune signals to disease-relevant T cells.

Core Technology and Platforms

Cue Biopharma’s development strategy is built around modular biologic platforms:

• Immuno-STAT® platform: A proprietary system of injectable biologics designed to selectively engage and modulate disease-specific T cells in vivo. The platform is intended to present defined signals to T cells to drive desired immune responses.
• CUE-100 series: A series of interleukin 2 (IL-2)-based Fc-fusion biologics that present two coordinated signals to T cells. Signal #1 consists of a tumor-specific peptide linked to a major histocompatibility complex (pMHC) to provide selectivity and specificity. Signal #2 is a rationally engineered IL-2 molecule designed to activate and expand targeted T cells while reducing broad systemic activation and the dose-limiting toxicities associated with traditional IL-2 therapies.
• CUE-101: Cue Biopharma’s most advanced clinical-stage candidate from the CUE-100 series. It is designed to activate and expand HPV16 tumor-specific T cells by presenting HPV E7-derived antigen (Signal #1) together with an engineered IL-2 variant (Signal #2). CUE-101 has been evaluated in a Phase 1 open-label, dose escalation and expansion study in recurrent/metastatic HPV16+ head and neck squamous cell carcinoma, both as monotherapy and in combination with pembrolizumab.
• CUE-102: A clinical candidate from the CUE-100 series targeting Wilms’ Tumor 1 (WT1) expressing cancers. It is designed to activate and expand WT1-specific T cells by presenting WT1 peptide to the corresponding T cell receptor. Company communications describe WT1 as an oncofetal protein over-expressed in multiple solid tumors and hematologic malignancies. CUE-102 has been studied in a Phase 1 open-label trial in late-stage colorectal, gastric/gastroesophageal junction, pancreatic and ovarian cancers expressing WT1 and is also being evaluated in an investigator-sponsored trial in recurrent glioblastoma multiforme.

Autoimmune Disease Focus and CUE-401

In addition to oncology, Cue Biopharma emphasizes a strategic focus on autoimmune disease. The company describes CUE-401 as its lead autoimmune asset and a first-in-class tolerogenic biologic. CUE-401 is characterized as a bifunctional molecule designed to act mechanistically as a master switch for regulatory T cell (Treg) differentiation and tolerance induction. It combines a transforming growth factor beta (TGF-β) “breathing-mask” moiety with Cue Biopharma’s clinically validated IL-2 mutein in a single injectable biologic. The goal is to restore immune homeostasis and tolerance in autoimmune conditions by promoting regulatory rather than pro-inflammatory immune pathways.

Company statements indicate that Cue Biopharma has engaged with the U.S. Food and Drug Administration through a pre-IND process to support advancement of CUE-401 toward investigational new drug (IND) submission for autoimmune disease indications. This reflects a broader corporate priority to advance autoimmune programs as a next stage of growth.

Collaborations and Partnered Programs

Cue Biopharma supplements its internal pipeline with strategic collaborations:

• ImmunoScape collaboration: Cue Biopharma entered into a collaboration and license agreement with ImmunoScape Pte. Ltd. to develop a novel in vivo cell therapy approach for solid tumors. Under this agreement, ImmunoScape will combine its proprietary T cell receptor (TCR) therapies with Cue Biopharma’s CUE-100 series Immuno-STAT T-cell engagers in a “Seed-and-Boost” strategy. A minimal dose of tumor-specific TCR-engineered T cells (Seed) is followed by administration of TCR-matched IL-2 Immuno-STAT molecules (Boost) to selectively expand and activate tumor-reactive T cells in vivo. Cue Biopharma has granted ImmunoScape licenses to research, develop and commercialize CUE-100 series molecules, including CUE-101 and CUE-102, for oncology indications, while retaining certain research rights and receiving equity and financial consideration.
• Boehringer Ingelheim collaboration: Cue Biopharma has a strategic research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize CUE-501, described as a differentiated B cell depletion therapy for autoimmune and inflammatory diseases. Under this agreement, Cue Biopharma receives upfront and potential milestone payments while contributing its biologics expertise to the partnered program.

Pipeline Orientation

Across company disclosures, Cue Biopharma references a pipeline of biologic candidates that includes:

• CUE-101, a clinical-stage program in HPV16+ head and neck cancer, including combination therapy with pembrolizumab.
• CUE-102, a WT1-targeted IL-2-based biologic in multiple WT1-expressing cancers and in an investigator-sponsored trial in recurrent glioblastoma multiforme.
• CUE-401, the lead autoimmune asset designed to re-establish immune tolerance through Treg differentiation.
• CUE-501, a partnered B cell depletion therapy for autoimmune and inflammatory diseases under collaboration with Boehringer Ingelheim.

In addition, Cue Biopharma has previously referenced CUE-103 and other candidates in its development pipeline, reflecting a broader application of the Immuno-STAT platform to different disease targets.

Business Model and Revenue Sources

Cue Biopharma’s disclosures indicate that it is a clinical-stage company, meaning its drug candidates are in human trials and it does not rely on approved commercial products for primary revenue. Instead, the company reports collaboration revenue from agreements with partners such as Boehringer Ingelheim and ImmunoScape. These collaborations include upfront payments, potential milestone payments, equity stakes and royalties on future net sales, alongside research and development contributions.

The company also raises capital through public offerings of common stock and related securities. For example, Cue Biopharma has announced underwritten public offerings of common stock and warrants, conducted under an effective shelf registration statement on Form S-3. Such financings provide funds to support clinical development, platform advancement and general corporate purposes.

Leadership and Governance

Cue Biopharma describes itself as being led by an experienced management team with deep expertise in immunology, immuno-oncology, protein engineering and the clinical development of protein biologics. In company filings, the board of directors has appointed new executive leadership to support the next stage of growth, including a transition in the chief executive role and associated employment and advisory agreements. These governance disclosures highlight an emphasis on experience in T cell therapeutics, cell and gene therapy and drug development across biotechnology and pharmaceutical organizations.

Regulatory and Corporate Structure

According to SEC filings, Cue Biopharma, Inc. is incorporated in Delaware and files periodic and current reports with the U.S. Securities and Exchange Commission under Commission File Number 001-38327. The company uses Form 10-K, Form 10-Q and Form 8-K to disclose financial results, material agreements, leadership changes and other significant corporate events. It also utilizes shelf registration statements on Form S-3 to facilitate securities offerings.

Risk Profile and Stage

As a clinical-stage biopharmaceutical company, Cue Biopharma operates in a high-risk, research-intensive segment of the biotechnology industry. Its drug candidates are subject to extensive clinical testing and regulatory review, and there is no assurance that any particular program will achieve regulatory approval. The company’s reliance on external financing and collaboration revenue is reflected in its financial statements and public offerings.

Frequently Asked Questions